Successful Sequential Treatment for Severe Asthma Coexisting COVID-19 via Budesonide/Glycopyrrolate/Formoterol Fumarate

Int J Gen Med. 2021 Feb 4;14:357-359. doi: 10.2147/IJGM.S291695. eCollection 2021.


Awareness of the management of coronavirus disease 2019 (COVID-19) and airway diseases can effectively help clinical physician during the coronavirus pandemic. Herein, we elucidated a COVID-19 case coexisting with severe asthma. Budesonide/glycopyrrolate/formoterol fumarate (BGF) was used as sequential medicine to systemic glucocorticoids for his persisted symptoms related to bronchospasms. Our case suggests patients with long-term airway diseases like asthma probably attribute their symptoms to COVID-19 instead of primary diseases, which make it more difficult in the symptom control. BGF is able to be an effective and convenient choice as sequential medicine to systemic glucocorticoids in some refractory asthmatic patients complicated with COVID-19.

Keywords: asthma; budesonide/glycopyrrolate/formoterol fumarate; coronavirus disease 2019; sequential treatment.

Publication types

  • Case Reports

Grants and funding

This work was supported by Zhuhai science and technology innovation Bureau (grant number ZH22036302200021PWC).